|
May 24
|
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
|
|
May 24
|
Sector Update: Health Care Stocks Advance Pre-Bell Friday
|
|
May 24
|
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
|
|
May 24
|
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
|
|
May 24
|
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
|
|
May 23
|
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
|
|
May 9
|
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
|
|
May 7
|
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
|
|
Apr 18
|
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
|
|
Apr 4
|
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 18
|
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
|
|
Mar 14
|
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
|
|
Mar 11
|
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
|
|
Mar 5
|
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
|
|
Mar 5
|
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
|
|
Jan 29
|
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
|
|
Jan 11
|
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Dec 18
|
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
|
|
Dec 13
|
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
|
|
Sep 28
|
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
|